Experimental epigenetic CRISPR therapy silences hepatitis B DNA without cutting it

A Nature news report describes CRMA-1001, an experimental hepatitis B treatment from nChroma Bio and collaborators in Milan that aims to silence—not cut—viral DNA.

The treatment uses a catalytically inactive CRISPR-Cas9 protein delivered in lipid nanoparticles. Guided to hepatitis B DNA, it adds methyl chemical tags that repress viral gene activity.

It is designed to target both cccDNA, the persistent viral DNA reservoir in liver cells, and HBV DNA integrated into the host genome—two major barriers to curing chronic hepatitis B.

Reported preclinical results were promising in human liver-cell experiments and mice; testing in monkeys showed minimal, temporary side effects. These are not yet results from a completed human efficacy trial.

This is best described as a possible route to a “functional cure”:
long-term suppression of viral activity and antigens, rather than proven physical eradication of every viral DNA molecule.

The potential advantage over conventional CRISPR editing is avoiding DNA double-strand cuts, which could reduce risks such as unintended genome damage. Important open questions remain about durability, off-target methylation, delivery, and human safety and effectiveness.